{"nctId":"NCT00721955","briefTitle":"Staccato Loxapine in Agitated Patients With Bipolar Disorder","startDateStruct":{"date":"2008-07"},"conditions":["Bipolar I Disorder"],"count":314,"armGroups":[{"label":"Inhaled Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Inhaled Placebo"]},{"label":"Inhaled Loxapine 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Inhaled loxapine 5 mg"]},{"label":"Inhaled Loxapine 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Inhaled loxapine 10 mg"]}],"interventions":[{"name":"Inhaled Placebo","otherNames":["Staccato Placebo"]},{"name":"Inhaled loxapine 5 mg","otherNames":["ADASUVE 5 mg"]},{"name":"Inhaled loxapine 10 mg","otherNames":["ADASUVE 10 mg"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female adult patients with bipolar 1 disorder and acute agitation\n\nExclusion Criteria:\n\n* Agitation caused primarily by acute intoxication\n* History of drug or alcohol dependence\n* Treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in PANSS Excited Component (PEC) Score From Baseline Following Dose #1 of Staccato Loxapine, Compared With Placebo","description":"The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"4.77"},{"groupId":"OG001","value":"-8.1","spread":"4.90"},{"groupId":"OG002","value":"-9.0","spread":"4.67"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression-Improvement (CGI-I) Score Following Dose #1 of Staccato Loxapine, Compared With Placebo","description":"Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"0.99"},{"groupId":"OG001","value":"2.1","spread":"1.10"},{"groupId":"OG002","value":"1.9","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"CGI-I Responders","description":"Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":105},"commonTop":["Dysgeusia","Dizziness","Sedation","Headache"]}}}